Nickan Research Institute Journal of Renal Endocrinology 2423-6438 9 1 2023 01 01 Biomarkers in IgA nephropathy; an update to recent data e25120 e25120 10.34172/jre.2023.25120 EN Rokhsare Zareie Mahsa Asadollahi Hamedani https://orcid.org/0000-0002-7130-1201 Reyhaneh Sadeghian https://orcid.org/0000-0003-2974-7653 Yaser Khanchemehr https://orcid.org/0000-0002-3098-9329 Mahboubeh Belali Kharaji https://orcid.org/0000-0001-7592-7159 Elahe Zaremoghadam https://orcid.org/0000-0002-0550-0122 Negar Shahkarami https://orcid.org/0000-0001-8530-895X Atena Samareh Fekri https://orcid.org/0000-0002-9664-5924 Journal Article 10.34172/jre.2023.25120 2023 03 31 2023 06 26 Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.